Can the FDA Salvage Interchangeable Follow-On Biologics?
November 19, 2019
By: Ted Mathias
BioProcess Online / Biosimilar Development
BioProcess Online and Biosimilar Development published "Can the FDA Salvage Interchangeable Follow-On Biologics?", an article co-written by Axinn partner Ted Mathias.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
Sponsorship
Antitrust
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
Webinar
Intellectual Property
Hartford HealthCare Black and Red Gala 2025
Sponsorship
Antitrust
Informa CompLaw Antitrust West Coast Conference 2025
Speaking Engagement
Antitrust
Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
Axinn Viewpoints
Litigation & Trials